These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 18989636

  • 1. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [Abstract] [Full Text] [Related]

  • 2. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.
    Am J Ther; 2009 Nov; 16(3):215-23. PubMed ID: 19454860
    [Abstract] [Full Text] [Related]

  • 3. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P.
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [Abstract] [Full Text] [Related]

  • 4. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA.
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [Abstract] [Full Text] [Related]

  • 5. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
    Schwartz JI, Dunbar S, Yuan J, Li S, Miller DL, Rosko K, Johnson-Levonas AO, Lasseter KC, Wagner JA.
    J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
    Denker AE, Morelli G, Vessey LK, Li S, Yuan J, Dunbar S, Lewis NM, Taggart W, Wagner JA.
    Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
    [Abstract] [Full Text] [Related]

  • 7. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J.
    J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
    [Abstract] [Full Text] [Related]

  • 8. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
    Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, Van Hecken A, Depré M, Knops A, Gottesdiener K, Stoch A, Wagner J.
    J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
    [Abstract] [Full Text] [Related]

  • 9. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N, Kim BH, Lim KS, Kim SE, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [Abstract] [Full Text] [Related]

  • 10. Absence of a pharmacokinetic interaction between etanercept and warfarin.
    Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.
    J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
    Addy C, Jumes P, Rosko K, Li S, Li H, Maes A, Johnson-Levonas AO, Chodakewitz J, Stoch SA, Wagner JA.
    J Clin Pharmacol; 2009 Oct; 49(10):1228-38. PubMed ID: 19783715
    [Abstract] [Full Text] [Related]

  • 12. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ.
    Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812
    [Abstract] [Full Text] [Related]

  • 13. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ.
    Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium.
    Modi NB, Kell S, Simon M, Vargas R.
    J Clin Pharmacol; 2005 Aug; 45(8):919-26. PubMed ID: 16027402
    [Abstract] [Full Text] [Related]

  • 15. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
    Kosoglou T, Zhu Y, Xuan F, Black L, Johnson-Levonas AO, Martinho M, Statkevich P, Cutler DL.
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1509-16. PubMed ID: 22476387
    [Abstract] [Full Text] [Related]

  • 16. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ.
    J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
    [Abstract] [Full Text] [Related]

  • 17. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
    Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM.
    J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
    [Abstract] [Full Text] [Related]

  • 18. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
    Kirby LC, Johnson BM, Adams LM, Eberwein DJ, Zhang K, Murray SC, Lates CD, Blum RA, Morris SR.
    J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
    [Abstract] [Full Text] [Related]

  • 19. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
    Stockis A, van Lier JJ, Cawello W, Kumke T, Eckhardt K.
    Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
    [Abstract] [Full Text] [Related]

  • 20. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
    Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ.
    Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.